title: Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
abstract: Oral panobinostat (Farydak®), a potent nonselective histone deacetylase inhibitor, is approved in several countries for use in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) [USA] or relapsed and/or refractory MM (EU) who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory drug (IMiD). In a pivotal phase III trial (PANORAMA 1) in patients with relapsed or relapsed and refractory MM who had received one to three previous lines of therapy, progression-free survival (PFS) was significantly prolonged with panobinostat plus bortezomib and dexamethasone compared with placebo plus bortezomib and dexamethasone. The significantly favourable effect of panobinostat- versus placebo-based treatment on PFS was also observed in a subgroup analysis of patients who had previously received an IMiD, bortezomib plus an IMiD, or at least two lines of treatment including bortezomib and an IMiD. Panobinostat plus bortezomib and dexamethasone had a generally manageable tolerability profile, with the most frequent grade 3-4 adverse events being myelosuppression, diarrhoea, asthenia or fatigue, peripheral neuropathy and pneumonia. Thus, panobinostat, in combination with bortezomib and dexamethasone, is a useful addition to the available treatment options for patients with relapsed or refractory MM.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Greig
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D000077767:Panobinostat; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat
references.citation: Expert Rev Hematol. 2014 Feb;7(1):97-111
references.pmid: 24471924
references.citation: Cancer Res. 2006 Jun 1;66(11):5781-9
references.pmid: 16740717
references.citation: Cancer. 2011 Jan 15;117(2):336-42
references.pmid: 20862746
references.citation: Int J Clin Oncol. 2015 Jun;20(3):423-30
references.pmid: 25855312
references.citation: Blood. 2013 Oct 3;122(14):2331-7
references.pmid: 23950178
references.citation: Epigenetics. 2014 Nov;9(11):1511-20
references.pmid: 25482492
references.citation: J Clin Oncol. 2013 Oct 10;31(29):3696-703
references.pmid: 24019544
references.citation: Blood. 2006 Nov 15;108(10):3441-9
references.pmid: 16728695
references.citation: Haematologica. 2010 May;95(5):794-803
references.pmid: 19951978
references.citation: Lancet Oncol. 2014 Oct;15(11):1195-206
references.pmid: 25242045
references.citation: Lancet Oncol. 2013 Oct;14(11):1129-40
references.pmid: 24055414
references.citation: Cancer Lett. 2009 Aug 8;280(2):233-41
references.pmid: 19344997
references.citation: Leukemia. 2012 Jan;26(1):149-57
references.pmid: 21799510
references.citation: Leuk Res. 2013 Jul;37(7):829-37
references.pmid: 23582718
references.citation: Expert Rev Anticancer Ther. 2015;15(7):737-48
references.pmid: 26051506
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7
references.pmid: 23956208
references.citation: Leuk Lymphoma. 2012 Sep;53(9):1722-7
references.pmid: 22335534
references.citation: Lancet Oncol. 2014 Oct;15(11):1178-9
references.pmid: 25242046
references.citation: Haematologica. 2015 May;100(5):670-6
references.pmid: 25710456
references.citation: Leuk Lymphoma. 2012 Sep;53(9):1820-3
references.pmid: 22288662
references.citation: Ann Hematol. 2014 Jan;93(1):89-98
references.pmid: 24135804
references.citation: Leuk Lymphoma. 2008 Mar;49(3):502-7
references.pmid: 18297527
references.citation: Blood. 2016 Feb 11;127(6):713-21
references.pmid: 26631116